Clinical Trials Logo

Chemotherapy-Induced Neutropenia clinical trials

View clinical trials related to Chemotherapy-Induced Neutropenia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03846414 Not yet recruiting - Clinical trials for Chemotherapy-induced Neutropenia

Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia

Start date: February 13, 2019
Phase:
Study type: Observational

The aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia(CIN) of cancer patients in the real world.1000 patients with non-myeloid malignancy who is planned to receive PEG-rhG-CSF for CIN prevention and 500 patients with non-myeloid malignancy who is planned to receive rhG-CSF for CIN prevention or treatment were prospectively recruited.The primary outcome was cost-effectiveness and second outcome was febrile neutropenia,the incidence and duration of grade IV neutropenia,chemotherapy delay,incidence of reduced dose of chemotherapy and relative dose intensity of chemotherapy.

NCT ID: NCT03701841 Not yet recruiting - Clinical trials for Chemotherapy-induced Neutropenia

Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis

Start date: October 2018
Phase:
Study type: Observational

This trial is a multicenter, non-interventional, registered real-world clinical study. Based on available evidence and recommendations of guidelines, tumor patients with high risk of FN and eligible for all enrollment criteria were recruited into primary prophylaxis of PEG-rhG-CSF or secondary prophylaxis of PEG-rhG-CSF according to the real-world clinical pathway without randomization. All patients need to receive at least 2 cycles of PEG-rhG-CSF prophylaxis. Researchers will record the incidence of FN, RDI, FN-related hospitalization, antibiotic use, direct medical care and indirect medical care cost under the real clinical conditions, and assess the efficacy, safety and cost-effectiveness of PEG-rhG-CSF primary prophylaxis versus secondary prophylaxis through sub-group analysis and exploratory research.